Lipidated IL-22 Alone or Combined with Immunomodulatory Agents Improves Disease Endpoints and Promotes Mucosal Healing in a Mouse Model of Chronic Dextran Sodium Sulfate-Induced Colitis
Given the challenges in achieving long-term remission in IBD due to inflammation and mucosal damage, lipidated IL-22 presents a promising treatment option that directly promotes mucosal healing, unlike traditional immunomodulatory therapies.
Authors
- Thomas Damgaard Sandahl (ORCID: https://orcid.org/0000-0001-9807-6852)
- Rasmus Jørgensen (ORCID: https://orcid.org/0000-0003-0541-1602)
- Anders Dige (ORCID: https://orcid.org/0000-0001-9995-0329)
- Silvia D’Alessio (ORCID: https://orcid.org/0000-0001-7713-040X)
- Martijn van de Bunt (ORCID: https://orcid.org/0000-0002-6744-6125)
- Sidsel Støy (ORCID: https://orcid.org/0000-0003-1630-8395)
- Silvio Danese
- Anne Louise Kjølbye
Institutions
- Vita-Salute San Raffaele University (IT)
- Aarhus University (DK)
- Aarhus University Hospital (DK)
- Zealand Pharma (Denmark) (DK)
- Phoenix (Italy) (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT)
Publication Details
- Journal
- Digestive Diseases and Sciences
- Published
- 2025-03-26
- DOI
- https://doi.org/10.1007/s10620-025-09007-w
- Citations
- 2
- Primary Topic
- Microscopic Colitis
- Type
- article
- Field-Weighted Citation Impact
- 2.71
Funders
- Danish Agency for Science and Higher Education